Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sonoma PharmaceuticalsFRA:O8Z 34 Days Inventory is 98.65 as of Mar. 2026, which is 8% below its 10-year median of 106.90. GuruFocus rates FRA:O8Z with a GF Score™ of 34/100 and a GF Value™ of €6.04. The stock has 4 warning signs investors should review. Among 922 Drug Manufacturers companies, Sonoma Pharmaceuticals ranks better than 76.46% on this metric.
The historical rank and industry rank for Sonoma Pharmaceuticals's Days Inventory or its related term are showing as below:
FRA:O8Z'
s Days Inventory Range Over the Past 10 Years
Min: 71.23 Med: 106.9 Max: 127.38
Current: 106.69
During the past 13 years, Sonoma Pharmaceuticals's highest Days Inventory was 127.38. The lowest was 71.23. And the median was 106.90.
FRA:O8Z's Days Inventory is ranked better than 76.46% of 922
companies
in the Drug Manufacturers industry
Industry Median: 164.72
vs FRA:O8Z: 106.69
Sonoma Pharmaceuticals's Days Inventory
declined
from Mar. 2025 (126.26) to Mar. 2026 (98.65).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Sonoma Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.93.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sonoma Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.66.
Sonoma Pharmaceuticals (FRA:O8Z) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Sonoma Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Sonoma Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Sonoma Pharmaceuticals Days Inventory Related Terms
Sonoma Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Sonoma Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:O8Z vs YCBD, CVSI, AKAN: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonoma Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Sonoma Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonoma Pharmaceuticals (FRA:O8Z) has a Days Inventory of 98.65 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sonoma Pharmaceuticals and its competitors. This is near median its historical median of 106.90. Over the past decade, Sonoma Pharmaceuticals' Days Inventory has ranged from 71.23 to 127.38. According to the industry distribution chart, Sonoma Pharmaceuticals ranks #217 out of 922 companies in the Drug Manufacturers industry, placing it in the top 23.5%.
Is Sonoma Pharmaceuticals' Days Inventory too high?
Sonoma Pharmaceuticals' current Days Inventory of 98.65 is near median its 10-year median of 106.90. Over the past 10 years, this metric has ranged from a low of 71.23 to a high of 127.38. The Drug Manufacturers industry median Days Inventory is 164.72. Sonoma Pharmaceuticals' value of 98.65 is 40.1% below this industry median. Based on the distribution chart, Sonoma Pharmaceuticals ranks #217 out of 922 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sonoma Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sonoma Pharmaceuticals' Days Inventory compare to YCBD and CVSI?
According to the Drug Manufacturers industry distribution chart, Sonoma Pharmaceuticals ranks #217 out of 922 companies for Days Inventory. This places Sonoma Pharmaceuticals in the top 24% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.72. Sonoma Pharmaceuticals' value of 98.65 is 40.1% below this benchmark. Historically, Sonoma Pharmaceuticals' own Days Inventory has ranged from 71.23 to 127.38 over the past decade. While the company's 10-year median is 106.90 vs. the industry median of 164.72, Sonoma Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.72, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sonoma Pharmaceuticals's current Days Inventory of 98.65 is 40.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Sonoma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonoma Pharmaceuticals's current Days Inventory is 98.65, which is near median its own 10-year median of 106.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonoma Pharmaceuticals stock overvalued right now?
Sonoma Pharmaceuticals (FRA:O8Z) has a current Days Inventory of 98.65. The stock's GF Value™ is €6.04, compared to a current price of €2.72 — trading 55% below its estimated fair value. The current Days Inventory is 98.65, which is near median its 10-year median of 106.90 and 40.1% below the Drug Manufacturers industry median of 164.72. Sonoma Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Sonoma Pharmaceuticals (FRA:O8Z), the current Days Inventory is 98.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonoma Pharmaceuticals (FRA:O8Z) Overvalued in 2026?
Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued.
The current stock price of €2.72 is trading 55% below its estimated GF Value™ of €6.04.
Key valuation signals for FRA:O8Z:
Days Inventory: 98.65 (near median its 10-year median of 106.90)
GF Value™: €6.04 vs. price of €2.72 (55% below fair value)
Industry Position: 40.1% below the Drug Manufacturers median (#217 of 922)
No single metric tells the full story. See the FRA:O8Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
34GF Score
Get the complete analysis for FRA:O8Z
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:O8Z has been successfully added to your 
